GET DAILY SIGNALSMarker Therapeutics (MRKR) Earnings Preview: Key Expectations for Q3 2026
Key Takeaways
- Marker Therapeutics (MRKR) is expected to report third-quarter 2026 results around November 12, 2026, with a conference call scheduled for November 13, 2026.
- Wall Street consensus calls for a net loss of -$0.12 per share on revenue of approximately $2.12 million for the quarter ended September 30, 2026.
- The company has beaten consensus earnings per share (EPS) estimates in six of its last seven quarters, a track record that has helped shape investor sentiment heading into the report.
- In the year-ago quarter, Marker posted a loss of -$0.12 per share on $1.23 million in revenue, meaning analysts expect meaningful top-line growth this time around.
- As a clinical-stage biotech, cash runway and research and development progress will likely matter as much to investors as the headline EPS and revenue figures.
- For more on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Looking for data-driven trade ideas? Explore Trending AI Robots to discover AI-powered strategies across the market.
Why This Earnings Report Matters for Marker Therapeutics
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing T cell-based immunotherapies for cancer treatment. For a pre-revenue-stage biotech, quarterly earnings serve less as a measure of profitability and more as a checkpoint on cash burn, operational discipline, and clinical execution. The company has spent recent quarters narrowing its losses while revenue fluctuates, and investors will be watching whether that trend continues. With a small market capitalization and a relatively modest cash balance, the upcoming report is an important signal on how efficiently Marker is managing resources as it advances its pipeline. Against a backdrop of elevated scrutiny on biotech funding, the third-quarter update will help investors assess the company's near-term financial stability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Consensus Estimates
Analysts expect Marker Therapeutics (MRKR) to report a loss of approximately -$0.12 per share for the third quarter of 2026, according to consensus estimates. Revenue is projected to reach roughly $2.12 million, up from $1.23 million in the same period a year earlier. In the prior quarter (Q2 2026), the company reported a loss of -$0.09 per share, beating the -$0.25 consensus estimate by $0.16, and it has now beaten EPS expectations in six of its last seven quarters. However, Marker has not issued formal earnings guidance, so investors will rely heavily on analyst estimates and management commentary. Key metrics to watch include the rate of cash burn, research and development expenses, and any updates on clinical trial progress or strategic initiatives.
How Investors Might React
Sentiment heading into the report is cautiously optimistic, supported by Marker's recent streak of EPS beats and an uptick in expected revenue. Still, the stock is a micro-cap name with limited analyst coverage, which can amplify volatility around earnings. Key risk factors include the timing and magnitude of grant revenue recognition, ongoing operating losses, and any signs of a widening cash burn. Because clinical-stage biotechs often move on pipeline news rather than financial figures alone, investors will also be alert for any development updates included in the release or the subsequent conference call. A narrower-than-expected loss or a stronger revenue figure could reinforce the company's improving trajectory, while any indication of rising expenses or financing needs could pressure the shares.
What to Watch Going Forward
Beyond the headline numbers, investors should focus on a handful of forward-looking signals. First is the company's cash position and runway. As a clinical-stage firm with limited revenue, Marker depends on its balance sheet to fund operations, so any commentary on expected capital needs or potential financing will be closely watched.
Second is the trajectory of operating expenses. Recent quarters have shown some narrowing of losses, and investors will want to see whether that efficiency trend is sustainable without sacrificing research and development momentum.
Third is clinical and strategic progress. Updates on trial enrollment, data timelines, or partnerships could prove more consequential for the long-term story than a single quarter's EPS. Finally, watch how revenue is recognized, since grant-related income can create quarter-to-quarter volatility that distorts headline growth.
Investors should keep these factors in mind when evaluating the third-quarter results and management's outlook for the remainder of 2026.
Exploring AI-Powered Insights
In my own workflow, I’ve found Tickeron’s AI Screener helpful for quickly filtering biotech names like Marker Therapeutics alongside peers based on fundamentals and technical signals. It lets me scan for patterns and performance metrics without manual effort, which is especially useful when preparing for earnings season and comparing sector trends. The tool supports customizable filters that can surface ideas worth monitoring more closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MRKR turns negative, indicating new downward trend
MRKR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 83 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
MRKR moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
MRKR broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRKR entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRKR's RSI Oscillator exited the oversold zone, 36 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 72 cases where MRKR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for MRKR just turned positive on November 09, 2026. Looking at past instances where MRKR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRKR advanced for three days, in 185 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.224) is normal, around the industry mean (3.498). P/E Ratio (-2.349) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.784) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cell based immune therapeutics and vaccines for cancer treatment
Industry Biotechnology
Advertisement